Trial Profile
A prospective, multicenter, randomized, double-blind, placebo-controlled, 2-parallel group, phase 3 study to compare efficacy and safety of masitinib 9 mg/kg/day in combination with bortezomib and dexamethazone to placebo in combination with bortezomib and dexamethazone in the treatment of patients with relapsing multiple myeloma who received one previous therapy
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 27 May 2021
Price :
$35
*
At a glance
- Drugs Masitinib (Primary) ; Bortezomib; Bortezomib; Dexamethasone
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Sponsors AB Science
- 27 May 2021 This trial has been completed in Greece, according to European Clinical Trials Database record.
- 11 Feb 2021 This trial has been completed in Germany (Global End Date: 01 Feb 2017), according to European Clinical Trials Database record.
- 15 Jun 2019 This trial has been completed in France.